This suggests that passive immunization with tau antibodies is really a feasible therapeutic target and the CSF level of p-tau262/356 or from the microtubule binding area (MTBD) can function a helpful biomarker of tau pathology to watch tau therapeutics in clinical trials.The components that determine whether or not an amyloid filament may be detec